The Assessment of Sentinel Lymph Node Mapping Methods in Endometrial Cancer
Journal of Clinical Medicine · 21.01.2025 · 14 (3) · 676
DOI: 10.3390/jcm14030676 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 21.01.2025. Verfasst von Wiktor Szatkowski und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecological Oncology, Maria Skłodowska-Curie National Research Institute, Kraków Branch, 31-115 Kraków, Poland. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Sentinel lymph node biopsy (SLNB) is a minimally invasive technique used to assess lymphatic involvement in endometrial cancer (EC), offering reduced surgical morbidity compared to routine lymphadenectomy. Despite its widespread use, the optimal combination of tracers for SLN detection remains a subject of debate.
Methods
This retrospective cohort study included 119 patients with early-stage EC treated at the Maria Skłodowska-Curie National Research Institute of Oncology between 2016 and 2021. SLNB was performed using technetium-99m (Tc99m), indocyanine green (ICG), Patent Blue, or combinations of these tracers. Detection rates for unilateral and bilateral SLNs and the accuracy of metastasis identification were analyzed.
Results
The overall SLN detection rate was 97.5%. Individual tracer detection rates were 100% for ICG, 100% for Patent Blue, and 96% for Tc99m. Combined tracers achieved detection rates of 96.9% (Tc99m and ICG) and 97.3% (Tc99m and Patent Blue). Bilateral detection was highest with Tc99m and ICG (90.6%) and Patent Blue alone (91%). Metastases were identified in 12% of cases, with combined methods improving metastatic detection. Tc99m yielded no “empty nodes”, compared to 1.7% with Patent Blue and 0.8% with ICG.
Conclusions
While combining Tc99m with dyes did not significantly improve overall SLN detection rates, it enhanced metastatic identification and reduced false-negative results. These findings suggest that combined tracer methods optimize SLNB accuracy in endometrial cancer. Prospective studies are needed to confirm these results.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gynecological Oncology, Maria Skłodowska-Curie National Research Institute, Kraków Branch, 31-115 Kraków, Poland.
- Departament of Pathology, Maria Skłodowska-Curie National Research Institute, Kraków Branch, 31-115 Kraków, Poland.
- Departament of Radiotherapy, Maria Skłodowska-Curie National Research Institute, Kraków Branch, 31-115 Kraków, Poland.
ORCID-Profile: Wiktor Szatkowski
Zitieren
APA
Szatkowski, W., Pniewska, K., Janeczek, M., Ryś, J., Banaś, T., Muzykiewicz, K., Iwańska, E., Jakubowicz, J., Karolewski, K., Szadurska, A., & Blecharz, P. (2025). The Assessment of Sentinel Lymph Node Mapping Methods in Endometrial Cancer. Journal of Clinical Medicine, 14(3), 676. https://doi.org/10.3390/jcm14030676
Vancouver
Szatkowski W, Pniewska K, Janeczek M, Ryś J, Banaś T, Muzykiewicz K, et al. The Assessment of Sentinel Lymph Node Mapping Methods in Endometrial Cancer. Journal of Clinical Medicine. 2025;14(3):676. doi:10.3390/jcm14030676
BibTeX
@article{Szatkowski2025,
author = {Szatkowski, Wiktor and Pniewska, Karolina and Janeczek, Maja and Ryś, Janusz and Banaś, Tomasz and Muzykiewicz, Konrad and Iwańska, Ewa and Jakubowicz, Jerzy and Karolewski, Kazimierz and Szadurska, Agnieszka and Blecharz, Paweł},
title = {The Assessment of Sentinel Lymph Node Mapping Methods in Endometrial Cancer},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {3},
pages = {676},
doi = {10.3390/jcm14030676}
}
EUVIMED